The OASIS 4 trial demonstrated 16.6% mean weight loss at 64 weeks with adherence, comparable to injectable Wegovy 2.4 mg (Wharton et al., 2025)
[8] [9] For retatrutide specifically, follow the missed-dose guidance provided in your trial protocol or by your prescriber
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes
The mechanism likely involves rapid changes in retinal blood flow, increased vascular permeability, and alterations in growth factor expression as glucose levels normalize
The goal is contouring and it aims to reduce stubborn fat pockets that resist diet and exercise